Nanotechnology Now

• About Us
  
  • Advertising
  • Our Mission
  • Our Team
  • Comments
  • Friends
  • Contact
• Nanotechnology
• News
  
  • Current News
  • Press Releases
  • Submit Press
  • Press kit
  • Interviews
• Columns
• Products
  
  • Our Products
  • Books
  • Featured Books
• Directories
  
  • Companies/Academic
  • Events
  • Glossary
  • Best Of
• Career Center
• Nano-Social Network
• Nano Consulting
• My Account

Home > News > APP Announces FDA Acceptance of New Drug

May 10th, 2004

APP Announces FDA Acceptance of New Drug

Abstract:
American Pharmaceutical Partners, Inc. and American BioScience, Inc.today announced that the New Drug Application for ABRAXANETM has been accepted for filing with standard review by the U.S. Food and Drug Administration, indicating the FDA has determined that the application is sufficiently complete to permit a substantive review. The final portion of the NDA was submitted on March 8, 2004 under FDA's Fast Track designation, as a treatment for metastatic breast cancer.

Source:
APP

Bookmark:

Related News Press

Nanomedicine

Malvern specialist to explore use of Nanoparticle Tracking Analysis for characterizing extracellular vesicles at ISEV 2014 March 11th, 2014

Arrowhead to Present at Barclays Global Healthcare Conference March 11th, 2014

Production of Bioactive Material for Quick Treatment of Bone Damages March 10th, 2014

Production of New Type of Electrochemical Drug Sensors for Cardiovascular Diseases March 10th, 2014

	The latest news from around the world, FREE

Premium Products
	Only the news you want to read!  Learn More
	University Technology Transfer & Patents  Learn More
	Full-service, expert consulting  Learn More

Nanotechnology Now Featured Books